

**S P E A K E R S A N D C H A I R S**



**Adrian van den Hoven, Director General, Medicines for Europe**

Adrian van den Hoven has been director general of Medicines for Europe since September 2013. In his role he focuses on stimulating competition in off-patent medicine markets, fostering access to medicine, reducing medicine shortages and addressing major health crises, supporting policy measures for sustainable pricing, promoting efficient regulatory standards, and developing a coherent EU industrial strategy to support the long-term viability of the generic, biosimilar and value-added medicines industries. He is also member, and former president, of the European Medicines Verification Organization (EMVO) board for the implementation of serialization against falsified medicines, the Chair of the International Generic and Biosimilar medicines Association (IGBA) and a member of the joint industry advisory council of the Health Emergency and Response Authority (HERA).



**Michael Finn, Partner, Bird & Bird**

Michael's practice focuses on complex contentious intellectual property and technology matters, and domestic and international commercial disputes. He also has extensive experience in regulatory disputes and investigations, product liability, and judicial review. Michael has a particular focus on the life sciences and technology sectors. He has acted in some of the leading intellectual property, technology and commercial disputes in Ireland and have extensive experience advising on Irish Commercial Court litigation, and ADR. Michael advises on a wide range of litigation and regulatory matters involving patents, trade marks, copyright, designs, trade secrets and confidential information, often involving additional issues such as intermediary liability, data protection, competition and consumer law claims. He has also advised on leading Commercial Court cases and alternative dispute resolution processes in many sectors, in particular life sciences and technology. He thrives on helping clients to navigate the Irish Courts, particularly in the context of a complex multi-jurisdictional mandate, and to collaborate with others and find the right solution for matter in question. He also has extensive experience analysing clients' obligations and determining actions to be taken under product laws, both in the context of bringing products to market, and addressing unforeseen circumstances such as defects and recalls. Michael regularly advises clients in relation to the regulation of medicinal products and medical devices in Ireland and have built up a strong expertise in navigating clients through interactions with regulators, as well as the regulatory impacts of commercial transactions.



**Olga Solomon, Head of Unit, DG Santé, European Commission (inv)**

Olga Solomon studied Chemistry at the Aristotle University of Thessaloniki, Greece and holds an MSc in Food Science from the Gothenburg University, Sweden. Before joining the European Commission she worked for 5 years for a beverage producing company in Greece. She joined DG SANCO in 2000 and worked for 10 years in the field of Food Safety in particular dealing with legislation on Food Contact Materials, Food Additives and Enzymes. In 2010, she moved to the Directorate 'Health Systems and Products' where she worked in the field of substances of human origin before taking up a post in the pharmaceutical sector in 2011. She is currently the Head of the DG SANTE Unit responsible for Medicines: policy, authorisation and monitoring.



**Marco Greco, President, European Patients Forum (inv)**

Marco Greco has been President of the European Patients' Forum since 2014. He was chairman of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) from 2008 to 2014. He was the founder of the EFCCA Youth Group, and its leader from 2003 till 2007. He was appointed as patient representative by the European Commission in the Pharmacovigilance Risk Assessment Committee at the European Medicines Agency (EMA) from 2013 to February 2019. He has recently been selected as patient representative to EMA's Management Board for a three-year term starting on 15 June 2019. He holds a degree in Law from UCSC MILAN and a Ph.D. in Law and Religious Freedom. He is currently working as an attorney in his law firm.



**Alpha Indraccolo, VP and General Counsel, European IP and Regulatory Litigation, TEVA (inv)**

Alpha Indraccolo joined the European IP and Regulatory Litigation team at Teva in 2013. She has led the team since 2018 covering matters relating to IP and regulatory litigation as well as support to IP aspects of government affairs in the European region. Alpha is a qualified solicitor (England & Wales) with a MSc in Molecular Biology from New York University and a BA from Barnard College. Before joining Teva, Alpha worked in private practice at Bird & Bird, London specialising in patent litigation.



**Corinna Sundermann, Senior Vice President, IP Management, Fresenius Kabi**

Corinna Sundermann is heading the IP department of the Pharma Division at Fresenius Kabi. She joined Fresenius Kabi in 2008 as a Manager and built the IP department from 1 to 40 FTE since then. She is Senior Vice President since 2012 and took over responsibility for copyright within Fresenius as well. Focus concerning patents is on generics, branded products, clinical nutrition and medical devices. Characteristic for the department is, to a certain extent, internal handling of litigation. Before joining Fresenius Kabi, she worked 10 years for an originator company, 5 years as a Head of Combinatorial Chemistry, 5 years in the IP department and is European Patent Attorney since 2006. She holds a Dr. rer. nat. from the University of Jena and a diploma in chemistry from the University of Frankfurt.



**Sergio Napolitano, General Counsel & External Relations Director, Medicines for Europe**

Sergio Napolitano is General Counsel and External Relations Director at Medicines for Europe. At Medicines for Europe since January 2013, in 2018 he was nominated in a list of the 50 most influential people worldwide in IP law, policy and business. Before joining Medicines for Europe, Sergio Napolitano worked in the Directorate General for External Policies of the European Parliament and at the Permanent Representation of Italy to the EU on multilateral, plurilateral and bilateral trade negotiations, EU investment policy and IPR. Sergio Napolitano holds a degree in Law from the University of Naples Suor Orsola Benincasa and a LL.M. on EU and European Public Law from the University College of London (UCL).



**Stijn de Jong, Partner, Stibbe (inv)**

Stijn specialises in European competition law and has extensive experience handling high-profile and cutting-edge antitrust investigations and litigations. His practice focuses on litigation matters, government investigations, antitrust regulatory approval, and general antitrust counseling. He advises a wide range of clients in diverse industries, including pharmaceuticals,

consumer products, life sciences, transport, media, manufacturing and technology. Stijn has contributed articles to leading Dutch and European journals. In 2021, Stijn was seconded to Cravath, Swaine & Moore LLP in New York.



### **Morten Nissen, Partner, Bird & Bird**

Morten is a partner and co-head of our international Competition & EU group. He also leads the Competition & EU team in Denmark. He has a particular focus on applying competition & EU law as a tool to achieve specific and measurable business objectives for our clients. Competition authorities act differently in different countries. He has a solid international experience and an outlook based on work for more than 12 years as a lawyer based in Brussels, which includes doing a number of fascinating competition cases in many countries across Europe as well as Asia. This first-hand experience helps him better navigate cases to obtain results that make a difference. His primary focus is on state aid, competition restricting agreements, and abuse of dominance. He has made numerous EU and national merger control notifications, and is always focused on optimising the business outcome and delivering competitive advantage. He is proud to say to have been involved in a high number of cases that made new case law. His sector experience is particularly strong in the pharmaceutical, copyright, media, IT, telecoms, passenger transport and international payment systems sectors. Over the years, he has represented clients in a large number of legal procedures before the EU Court of Justice in Luxembourg. Amongst these, he has won four appeal cases against the EU Commission, including a state aid case before the Grand Chamber of the EU court of justice which ultimately led to the EU Commission's Legal Service turning around and choosing Morten to represent the Commission in a number of other state aid cases. Until 2012, he was a partner in the Brussels office. He left Bird & Bird to start a pharmaceutical business and other start-ups. After this, he was Of Counsel at a leading Danish firm, before finding his way home back to Bird & Bird in 2018. At Bird & Bird, he benefits from a truly international set-up and he has a personal network that allows him to know exactly who is well placed to handle a particular case in one of our many offices around the world. It particularly allows him to pull in points of view from a high-quality pool of 65 competition lawyers around the world. Morten is a member of the World Competition, Law and Economics Journals Advisory Board (Kluwer) and co-author of 'Guide to EU Pharmaceutical Regulatory Law' (Kluwer).



### **Anna Vernet, Head of Unit, DG Competition, European Commission**



**Steve Rowan, Vice President, European Patent Office**

Stephen Rowan joined the EPO in January 2019 as Vice-President for DG1 – Patent Grant Process. He is responsible for the entire Patent Grant Process, from the receiving of applications up to and including opposition and the grant of the patent. This area also includes Quality and Business and User Services. Located in The Hague, Steve Rowan is Site Manager for the branch of the EPO, which is the largest international organisation in the Netherlands. Before joining the EPO, Stephen Rowan held a number of senior leadership roles in the Intellectual Property Office of the United Kingdom. These included the position of Director of Registered Rights, responsible for the end to end processing of patent, trade mark and design applications and the associated tribunal functions. Stephen Rowan joined the UK IPO in March 1991 and, in addition to his operational roles, sat as a Principal Hearing Officer and worked on a range of policy issues covering industrial property and copyright. He was Head of the UK Delegation to the Beijing and Marrakesh Diplomatic Conferences and was seconded to the Prime Minister’s Strategy Unit (2004) and HM Treasury (2006) - working on the Gowers Review of IP. He has an LLB (Hons) from the University of the West of England.



**Jacob Westin, Head of Legal, Global Antitrust, Sandoz AG**

Based in its Basel, Switzerland HQ, Jacob is the global head of antitrust at Sandoz, a world leading generic and biosimilars company. Jacob advises on all antitrust issues arising in Sandoz’ business operations including antitrust compliance, advocacy, policy, investigations, M&A and more. Jacob joined Sandoz in October 2023 from Takeda Pharmaceuticals, where he had a dual role as head of legal, Nordics and head of antitrust Europe, based in Stockholm. Jacob came to Takeda as a result of its acquisition of Shire in 2019, having joined Shire in 2016 after relocating back to Sweden from the UK where he had been with GSK as its London HQ-based assistant general counsel, primarily responsible for competition law matters. Prior to joining GSK in 2008, he held various senior in-house roles after moving to the UK in 2000. A Swedish national, he started his career with the Swedish Competition Authority, serving for four years before joining a global law firm in Stockholm to practice competition law. Jacob earned his Swedish law degree at Uppsala University and an LLM in European law at the University of Essex. He has taught competition law at Swedish universities and written several books and articles on the subject. Jacob is also a regular speaker at various international competition law conferences.





**George Moore, Assistant General Counsel, Europe IP, Ex-NA IP Litigation, Viartis (inv)**

George Moore is Assistant General Counsel - Europe IP, Ex-NA IP Litigation, at Viartis. He currently leads the IP team at Viartis for Europe and the IP Litigation function for all ROW matters. He is a qualified solicitor (England & Wales) with a masters' degree in chemistry. He has over 15 years in-house pharmaceutical experience, having worked at Apotex in Canada and Sandoz in Germany. He previously worked in private practice in the UK, training and qualifying at Bristows, before then working at Allen & Overy.

**Oliver Bourne, Vice President, Legal and Compliance - EU and LATAM, Glenmark (inv)**



**Cristoph De Coster, Partner, Taylor Wessing**

As a patent lawyer, Christoph specialises in advising and representing national and international clients in complex patent litigation (including in particular cross-border proceedings). For almost 20 years, he has been leading, coordinating and supervising patent disputes for his clients before the German and European patent courts and authorities. He also prepares patent infringement and nullity opinions and advises on the structuring of patent-related transactions. Patent law advice and representation of clients from the pharmaceutical and medical device industries is a particular focus of Christoph's practice.



**Matthew Royle, Partner, Taylor Wessing**

Matthew specialises in patent litigation, opinion work, supplementary protection certificates (SPCs), paediatric extensions and regulatory advice. Matthew has a strong science background, holding a PhD in molecular immunology, meaning he gets to grips with the scientific facts of a case quickly. A leading individual in Chambers and is a rising star in litigation, Matthew has particular experience of acting for clients in the pharmaceutical, biotech and life sciences

sectors. He regularly co-ordinates pan-European litigation and has been involved in hearings in Germany, Netherlands, Belgium and Norway.



**Ann Keelan, Director Compliance & Ethics Europe, Teva**

Ann Keelan is co-chair of the Medicines for Europe Code of Conduct working group, and Director of Compliance & Ethics at Teva in a strategic European role. She is a solicitor with 25 years' experience in pharma, having initially joined the industry in IT project management with GlaxoWellcome. She has worked for numerous global pharma businesses, developing and implementing complex procedures, and contributing to major business change projects including Lean Six Sigma in manufacturing. Over the years Ann has nurtured a passion for developing and implementing corporate and local policies and SOPs. Outside work, Ann is an active Soroptimist (currently leading a project to combat period poverty in her city), a keen choir singer and artist, and an occasional volunteer archaeologist.



**Natasha Liston Williams, Head of Compliance Europe, Global Compliance, Viatris**

Natasha Williams is the Head of Compliance - Europe for Viatris, formed in November 2020 through the merger of Upjohn (a former division of Pfizer) and Mylan. Since joining the company in September 2018, Natasha leads the design, operation, and continuous improvement of the compliance program for Viatris' Developed Markets Europe businesses. Before joining Viatris, Natasha served as SVP of Privacy and Data Protection Officer at Teleperformance, where she was responsible for the development, implementation, and administration of Teleperformance's data privacy program in the UK & CEMEA region. As a former Global Litigation and Investigations Director at Sanofi, Natasha oversaw the company's cross-border discovery activities, including designing the strategy for the processing and transfer of information for legal proceedings or investigations, in compliance with data protection laws and blocking statutes. Natasha is Co-Chair of the Medicines for Europe Code of Conduct working group and contributed to the revised version of the Code issued in February 2021. She is also an annual lecturer for the Healthcare Compliance Leadership Program at INSEAD.



**Andreas Schillack, Head Legal & Compliance Region Europe, Sandoz**

2018 – today      Head Legal Region Europe at Sandoz  
2017 – 2018      Head Legal Region Western Europe at Sandoz  
2012 – 2017      Country Head Legal & Compliance Germany at Novartis  
2007 – 2011      Head of Legal Region Central Eastern Europe Middle East Africa at Merck & Co.  
1999 – 2007      Head of Legal Germany at Eli Lilly & Company  
1996 – 1999      Attorney at Law at Clifford Chance  
1995 – 1996      Attorney at Law at Kasper, Knacke, Schäuble



**Kristof Roox, Partner, Crowell & Moring**

Kristof Roox is co-managing partner of Crowell & Moring's Brussels Office. He is a partner in the Intellectual Property Group and focuses on IP litigation, and in particular on complex patent litigation in the life sciences sector. With over 25 years of experience, Kristof has an impressive reputation before the Belgian civil and administrative courts, and also litigates before regulatory authorities and in the European courts. He will also deal with litigation before the new Unified Patent Court. He is widely respected for his pragmatic and creative approach to solving business disputes and for his to-the-point counselling. In addition to traditional IP litigation and counselling, Kristof is widely recognized for his thought leadership in relation to the regulatory aspects of life sciences. He advises companies and trade associations on launch and marketing strategies, data exclusivity and market protection, parallel imports, promotional practices, rebates, pricing and reimbursement, distribution models, OTC products, health care reforms, competition law aspects, etc. Furthermore, Kristof is an experienced litigator across a broad range of commercial and civil matters, covering all aspects of dispute resolution including ADR. With his deep knowledge of private international law issues, he often tackles complex multi-jurisdictional questions and he is reputed for his broad knowledge of procedural law issues.





**Paul Csiszár, Director, DG Competition, European Commission**

After graduating from ELTE School of Law of Budapest, Paul Csiszár studied international comparative law and earned a second Juris Doctorate at Loyola Law School in the United States. Following his admission to the California Bar in 1986 he practiced as a corporate, securities and M&A lawyer in the US and then from 1997 in Europe with the international law firm of Squire Sanders until 2003 when he joined the public sector. Currently Mr Csiszár serves as one of the Directors of the Directorate General for Competition of the European Commission.



**Ann Henry, Partner, Bird & Bird**

Ann is a partner based in our Dublin office. She has been ranked as a "Leading Individual" in Dispute Resolution in Ireland for many years. Legal 500 2022 noted that she is recognised particularly for her role in a number of major patent disputes and data breach cases. In recent years she has successfully led some of the most complex Commercial Court cases in Ireland in both patent litigation (e.g. Apixaban) and data privacy (e.g. Schrems II). She has practised in both areas for many years. She was a co-founder of the Data Protection and Intellectual Property Committee of the Law Society of Ireland. Ann was Chair of the committee for 2016 to 2018 which coincided with the introduction of GDPR. She was appointed by the Government to the Data Forum which sat in the Department of An Taoiseach and considered data related issues relevant to Ireland's digital economy. Ann was a member of the steering committee for the successful inaugural Dublin Data Summit held in the National Convention Centre in 2017 with 1000 attendees and an array of international speakers. She has been involved in a broad spectrum of intellectual property disputes as regards trade marks, breach of copyright as well as patent litigation. The sectors she focuses on tend to reflect Ireland's FDI economy: pharmaceutical, technology, retail and financial services. Whilst practising in field of contentious data privacy often involves her managing regulatory disputes (judicial reviews, statutory appeals and prosecutions) she has also acted for clients in the downstream consequences of data breaches which have included advising on investigations, commercial litigation and on reputation management. In feedback from clients they value her for her sharp focus on the litigation strategy, her grit and resilience throughout the case and her determination to do all she can to deliver a "win" for them.



**Giovanni Napolitano, Director of Intellectual Property and Competition Policy, WIPO (inv)**



**Petra Bohanec Grabar, Group Head, IP Small Molecules, Sandoz**

Petra Bohanec Grabar is a Slovenian and European Patent Attorney and holds a diploma of Patent Litigation in Europe from the University of Strasbourg. Petra has extensive experience working in house. In her current role as Group Head, IP Small Molecules in Sandoz Petra leads a team of patent practitioners supporting development, in licensing and launch of generic products on global markets. Petra holds a PhD in Biochemistry and Molecular Biology from the Faculty of Medicine, University of Ljubljana and is an author of twelve peer reviewed articles in the field of pharmacogenetics.



**Otto Swens, Patent and Life Sciences Regulatory Litigator, Vondst**

Otto Swens (1970) is co-founder of Vondst Advocaten (2007). Otto's practice deals with all aspects of intellectual property, but it has a strong focus on patents, Otto advises and litigates patents particularly in the field of pharma & biotech, chemistry, medical devices and mechanical engineering. Further, Otto is active in the life sciences regulatory practice. He advises amongst others about marketing authorisations, (orphan) medicinal products, paediatric indications and incentives and rewards for pharmaceutical research, such as data exclusivity, market exclusivity and patent term extensions (SPC's), Otto also advised on medicinal product pricing, parallel imports, reimbursements, product liability and promotion. Otto represents clients in litigation before the Dutch national courts, the General Court / European Court of Justice in Luxembourg and (as per 1 June 2023) the Unified Patent Court, such as the local division in The Hague, the Central Division and the Appeal Court in Luxembourg. Otto is recognized internationally as patent and life sciences specialist in guides such as Chambers Europe, Chambers Global, Legal500, IAM Patent, Juve and Managing IP. Otto also regularly lectures and publishes on patent law and life sciences topics, at conferences and

in national and international journals. Otto is co-author of Oxford University Press handbook 'Pharmaceutical, Biotechnology and Chemical Inventions: World Protection and Exploitation'.

Otto is President of the Dutch Advisory Committee IP legislation and also a member of various professional associations, including AIPPI, EPLAW, the Dutch Association of Pharmacy and Law, PTMG and the Dutch IP litigator association VIEPA, with specialisation patent law. Otto has registered the following principal (and secondary) legal practice areas in the Netherlands Bar's register of legal practice areas (rechtsgebiedenregister): Intellectual Property (Intellectueel Eigendomsrecht). Based on this registration, Otto is required to obtain ten training credits per calendar year in each registered principal legal practice area in accordance with the standards set by the Netherlands Bar.



### **Arvid van Oorscot, Partner, Vondst**

Arvid litigates on patents at national and European level and is also increasingly involved in pharmaceutical law. He regularly publishes and lectures on (international) enforcement of intellectual property rights and related topics. Arvid is in verschillende gezaghebbende editorials opgenomen waaronder Chambers Europe ("He is noted by several sources who are impressed by his growing practice and his contribution to high-profile cases involving patents and design rights") en IAM Patent 1000 ("He is phenomenal – he's really making a name for himself."). Arvid is an active member of various professional and industry associations, including HollandBIO, EPLAW and AIPPI. Arvid studied at the Vrije Universiteit of Amsterdam and Northwestern Law School in Chicago and was sworn in as a lawyer in 2004. Arvid has registered the following main (and sub) legal areas in the register of legal areas of the Dutch Bar Association: Intellectual Property Law. On the basis of this registration, Arvid is obliged to obtain ten training points every calendar year in each registered main legal area in accordance with the standards of the Dutch Bar Association.



### **Saufung Ma, Accord Healthcare (inv)**

Saufung looks after Accord Healthcare's IP and regulatory EMENA strategies. His roles include managing litigations, patent prosecution, brand protection and IP licensing.



**Agnieszka Deeg-Tyburska, General Counsel, Board Member, Polpharma**

Agnieszka Deeg-Tyburska works as the General Counsel of Polpharma Group since 2015. Currently, at Polpharma she manages Legal, Compliance, Security and Patent teams. She is also the Vice-President of the Legal Committee of Medicines for Europe and also holds the title of a Certified CERP Mediator. She has been associated with the pharmaceutical industry for many years, representing generic and innovative producers. In her so far career, Agnieszka has extensive experience in the field of large and sophisticated transactions, with particular emphasis on acquisitions of public companies, investment transactions of venture capital funds, representing international financial institutions in the acquisition of Polish banks and leasing companies. She also prepared MBO and LBO structures. She has represented a number of financial institutions and borrowers in loan programs, issues of debt securities and financial leasing transactions. Email: [agnieszka.deeg-tyburska@polpharma.com](mailto:agnieszka.deeg-tyburska@polpharma.com)



**Dr. Anja Lunze, LL.M., Partner, Taylor Wessing**

Anja heads our Life Sciences & Healthcare group in Germany. She is a specialist lawyer for intellectual property law, admitted as representative before the Unified Patent Court (UPC) and has specialized in patent law for 20 years. Anja manages and coordinates complex, multinational patent infringement proceedings and litigates in German courts and the UPC. She advises on freedom to operate and product launches and negotiates license as well as research and development negotiations. In particular, Anja represents clients from the fields of pharmaceuticals, biotech, personalised medicine and precision medicine as well as from the chemical and medical device industries. She advises on related issues of digitisation and artificial intelligence in the life science sector. Having spent time in Geneva, Strasbourg, Tokyo and London, Anja has intercultural competence and language skills (including English, French and Japanese).



**Francisco Manrique, Associate General Counsel, Insud Pharma**

Francisco Manrique is the Associate General Counsel at Insud Pharma, a leading pharmaceutical multinational company, bringing over a decade of extensive expertise in the life sciences domain. Francisco has navigated diverse legal landscapes, encompassing agreements spanning from R&D to manufacturing, distribution, IP licensing, as well as regularly participating in BD and M&A transactions. His areas of expertise include managing complex litigation, addressing quality-related concerns such as recalls and product liability issues, and ensuring compliance with regulatory standards.



**Christian Dekoninck, Partner, Taylor Wessing**

Christian co-head's the Patents & Innovation team in Belgium and the Netherlands. Christian is recognised as a leading IP litigator and is particularly well-known for advising life sciences companies. His practice covers all aspects of intellectual property law. Clients describe Christian as a compelling patent litigator, and particularly value his experience advising on IP issues specific to the life sciences industry, such as the interface between IP and regulatory issues. Christian advises on multinational infringement litigation of patents, copyrights, trademarks, and design rights. His regulatory experience includes supplementary protection certificates, the Bolar exemption and data exclusivity.



**Martijn de Lange, Patent Examiner, Patent Office of the Netherlands**

Dr. Martijn de Lange was trained as a chemist. Since 2001 he works for the Netherlands Patent Office. He divides his time between examining patent applications and applications for supplementary protection certificates (SPCs) for pharmaceuticals, and the paediatric extensions thereof. He also represents the Netherlands Patent Office at the Dutch courts when appeals against decisions on SPCs are filed and has been involved in the drafting of the observations of the Netherlands government in the last 7 referrals before the Court of Justice of the European Union. In March 2021



and January 2023 he organized SPC Expert Meetings where examiners from the national patent offices in Europe informally discussed the latest case law and developments.



**Dolores Cassidy, Head of Patent Examination, Patent Office of Ireland**

Dolores Cassidy, B.Sc. Ph.D., graduated from University College Dublin with a Ph.D. in Physical Chemistry. In 1998 she joined the Intellectual Property Office of Ireland as a Patent Examiner, with particular responsibility for the examination of Supplementary Protection Certificates (SPCs). In 2021 she was promoted to the position of Head of Patent/SPC Examination at the Irish Office.



**Roberto Romandini, LL.M. Munich; independent; former Affiliated Research Fellow (2020-2022) and Senior Research Fellow (2012-2019) of the Max Planck Institute for Innovation and Competition (inv)**

Dr Roberto Romandini holds a law degree from the University of Pisa and an LL.M. degree from the University of Munich, where he specialised in patent law. He completed his Ph.D. thesis on the patentability of human stem cells at the LMU in Munich, before practising intellectual property law for 5 years at a leading IP firm in Milan. From 2012 to 2019, he worked as a Senior Research Fellow at the Max Planck Institute for Innovation and Competition in Munich. In this position, he led and co-authored the first MPI study on SPCs, published in 2018. In 2020-2022, on behalf of the Max Planck Institute, he wrote the "Study on the Options for a Unified Supplementary Protection Certificate (SPC) System in Europe" for the European Commission. The views expressed in this study (and in today's presentation) are the author's own and do not reflect the views and opinions of the European Commission or the EPO Boards of Appeal, for which Dr Romandini has been working since 2019.

**Kamil Kiljanski, Head of Unit, DG Grow, European Commission (inv)**



**Imre Gonda, Director of Legal and IP Department, Gedeon Richter**

Imre Gonda has been practicing national and international IP law for more than 20 years. Currently he is the director of Legal and IP Department one of the largest pharmaceutical companies in the Central European region which is very active in both areas, research of originating pharmaceuticals and generic product development. Previously he was head of Industrial Property Department. Before he joined Gedeon Richter Plc., he filled different positions in the Hungarian Intellectual Property Office, for 10 years he was the deputy-head of Trademark, Model and Design Department. He was responsible for managing and supervising the operation of national and international trademark, geographical indication and design sectors. He was involved in norm setting procedures including the preparation of amendments of laws and the creation of new international legal instruments. He participates in different international forums on a regular basis at WIPO and EU institutions, he was the elected vice-chair for eight cycles of the WIPO Standing Committee on the laws of Trademarks, Designs and Geographical Indications which forum was chaired by him for two years. He was participating in different forums of EUIPO (e.g. Management Board and Budget Committee; Liaison Meeting) in his national capacity for a considerable time period. He is qualified as a lawyer in Pázmány Péter Catholic University (Budapest) and did post graduate studies in European Law (LLM). He has written and edited several publications and books.



**Karin Pramberger, Head of IP, Polpharma Group**

Karin joined the Polpharma Group as Head of IP in 2018. She is responsible for all global patent and trade mark related activities. Prior to joining the Polpharma Group, Karin worked in various positions in the patent departments of Pharmaceutical companies after having spent 7 years in a law firm in Vienna, Austria, where she became European and Austrian patent and trade mark attorney. She studied Biotechnology in Vienna, Austria, and at the Ecole Nationale Supérieure de Chimie de Paris, France. In 2017 she graduated with an LLB from the University of London. Since 2005 she is a tutor at CEIPI, University of Strasbourg, for the pre-exam and the C-part of the European Qualifying Exam, and since 2006 she is an active member of the Legal Affairs Committee of Medicines for Europe.



**Jiri Slavik, Director IP, Adalvo**

Jiri Slavik is a dual qualified Czech & European Patent Attorney and a registered UPC representative (European Patent Litigator). He is a fully engaged IP professional having now more than 9 years of experience working as an in-house patent counsel in the pharmaceutical industry, where he is involved in various IP aspects of the Generic & Value-Added Medicines development – as the Director of IP, Jiri is now part of the IP team at Adalvo, a leading global B2B pharmaceutical company. Outside of the pharma industry, Jiri sometimes practices as a solo patent attorney and was elected as a full member of the *epi* Litigation Committee for the term 2023-2026 for the Czech Republic. Jiri has also occasionally published articles on the Kluwer Patent Blog.



**Beatriz Díaz de Escauriaza, Head of IP Legal - Insud Pharma**

Beatriz is currently Head of the IP Legal Practice at Insud Pharma Group, a diversified biopharmaceutical business based in Madrid, Spain, that she joined in 2017. In her role as Head of IP Legal, Beatriz is a member of the International Trade and IP Committee of the International Generics and Biosimilars Association (IGBA). Before joining Insud Pharma, Beatriz worked in private practice as a patent litigator in Madrid with Bird & Bird where she specialized on pharma patent litigation and intervened before the European authorities, having also acted before the European Court of Justice at Strasbourg. Beatriz holds a degree in Law and a Master Degree in Intellectual Property by the University of Alicante (X Magister Lvcentinvs).



**Alexander Ott, Principal IP Counsel, Sandoz**

Alex is a German and European Patent Attorney and Senior IP Counsel at Hexal AG/Sandoz, located in Holzkirchen, Germany. He joined Sandoz in 2008 after 3.5 years in private practice at Wuesthoff & Wuesthoff, Munich. In his current role, he is focusing primarily on guiding the global development, supporting multi-jurisdictional IP litigation, and enabling launches worldwide of Sandoz's biosimilars. Since 2019, Alex is also representing Sandoz at the Legal Affairs Committee of MfE.



**Karen Gallagher, Partner, Pinsent Masons**

Karen is a partner and life sciences lead for Pinsent Masons in Ireland. She has over 10 years' experience in contentious intellectual property work, providing strategic advice to clients in complex patent disputes and trade mark, design and copyright litigation. She acts for a broad range of clients including global pharmaceutical companies, international brands, and technology and media companies. Karen has represented clients before all levels of the Irish Courts, including in precedent setting patent infringement and revocation proceedings, trade mark infringement disputes, trade mark appeals, copyright and database rights disputes, and passing off claims. Karen is a registered trade mark agent and is a committee member of the INTA Public Information Committee 2024-2025. Karen is a recommended lawyer in Legal 500 EMEA 2024 in the areas of Intellectual Property, Healthcare and Life Sciences, and Dispute Resolution. She is ranked silver by World Trademark Review 2024, and has been recognised as a Rising Star in 2022 and 2023 by IP Stars.



**Ana Martí, General Counsel & IP, Medichem**

Ana Martí is General Counsel at Medichem, S.A., a Spanish headquartered company devoted to the development and manufacture of active pharmaceutical ingredients and generic medicines. Her role includes, in addition to legal, IP and regulatory affairs of the group of companies. She has more than 20 years' experience in the pharmaceutical industry, mainly acquired in the generic sector. She is qualified as a Spanish attorney at law and completed executive education at ESADE Business School. Before joining Medichem, she worked several years at a Spanish law firm advising life science clients on commercial transactions and regulatory and IP matters. Ana has also participated as co-author of a book on pharmaceutical marketing and is currently member of the Board of Medicines for Europe.



**Ingrid Sollerer, General Counsel & Chief Compliance Officer, Sandoz**

Dr. Ingrid Sollerer is General Counsel and Chief Compliance Officer at Sandoz. She joined Sandoz GmbH, Austria in April 1998 and moved on to Novartis International AG in Basel, Switzerland where she held the position of a Senior Corporate Counsel, Mergers & Acquisitions and Competition Law from 2001 to 2007. Since 2008 she was heading the Legal Departments for Western Europe, Middle East/Africa, the global Business Units Oncology Injectables and Anti-Infectives and holding the position of the Global Head Legal Biopharmaceuticals and Deputy General Counsel at Sandoz. In 2016 she joined Novartis Oncology as Global Head Legal Transactions and Cell&Gene in East Hanover, USA before rejoining Sandoz in 2019 in her current position. Ingrid holds a degree of law from the University of Innsbruck, a Diploma of international law at the University of Seville/Spain and obtained a doctorate in law (PhD) in 2001 at the University of Innsbruck.

**Mark Ferguson, General Counsel Europe, Viatrix**

**Barbara Majcen, General Counsel EU Generics & Procurement, Teva**

**Thomas Gibbs, General Counsel, Accord (inv)**



**Elisabeth Stampa, President, Medicines for Europe**

With more than twenty years in the industry and as an experienced business leader with track record in growing and transforming businesses, Elisabeth serves currently at the Board of Medichem SA. She has been the former CEO of Medichem SA., transforming a pure API company into a competitive vertical integrated player. She held other executive positions at Corporate family business (Medichem SA and the former Combino Pharm SL), having started her career at Laboratorios Esteve. She holds a BSc in Pharmacy (UB, Spain) and a MBA (ESADE, Barcelona, Spain). She also serves on the Board of Trustees at the IQS in Barcelona. Elisabeth has been an active member of international associations throughout her professional career and advocates for legislative changes that improve patient accessibility and strengthen the European industry at a global level.